You have 9 free searches left this month | for more free features.

Diffuse large B-cell lymphoma

Showing 26 - 50 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Chidamide in Recurrent and Refractory Diffuse Large b

Enrolling by invitation
  • Diffuse Large B-cell Lymphoma
  • Suzhou, Jiangsu, China
    Second Affiliated Hospital of Soochow University
Jan 9, 2023

DLBCL, Not Otherwise Specified Trial in Chongqing (selinexor)

Recruiting
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • Chongqing, Chongqing, China
    Chongqing University Cancer Hospital
Mar 27, 2023

Diffuse Large B Cell Lymphoma,DLBCL Trial in Chengdu (PM 8.4 mg/m2, PM 11.2 mg/m2)

Recruiting
  • Diffuse Large B Cell Lymphoma,DLBCL
  • PM 8.4 mg/m2
  • PM 11.2 mg/m2
  • Chengdu, Sichuan, China
    West China Hospital Sichuan University
Jan 15, 2023

Living Conditions of Diffuse Large B-Cell Lymphoma or Follicular

Completed
  • Diffuse Large Cell Diffuse Lymphoma
  • Follicular Lymphoma
  • Questionnaires
  • Collection of clinical data and treatments
  • Dijon, France
    Chu Dijon Bourogne
Jan 31, 2023

Diffuse Large B Cell Lymphoma Trial in Tampa (Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Itacitinib
  • Chimeric antigen receptor (CAR) T-cell therapy
  • Tampa, Florida
    Moffitt Cancer Center
Mar 6, 2023

Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • Gut microbiome analysis
  • Bologna, Italy
    Institute Of Hematology "Seràgnoli"
Feb 10, 2023

DLBCL Trial in San Juan (PF-07901801, Tafasitamab, Lenalidomide)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • San Juan, Puerto Rico
    Auxilio Mutuo Cancer Center
Jan 19, 2023

Diffuse Large B Cell Lymphoma Trial (Pembrolizumab, Rituximab, Ifosfamide)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Headington, Oxford, United Kingdom
  • +1 more
Nov 2, 2022

Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

Not yet recruiting
  • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • +21 more
  • Biopsy
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 7, 2023

Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Low-Dose Decitabine plus anti-PD-1
  • Beijing, Beijing, China
    ChinaPLAGH
Apr 18, 2023

Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Homburg (R-miniCHOP + Acalabrutinib, R-miniCHOP)

Not yet recruiting
  • Large B-cell Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Homburg, Saarland, Germany
    Saarland University Medical Center
Apr 19, 2023

Recurrent DLBCL, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma Trial in Duarte (Biopsy,

Not yet recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +11 more
  • Biopsy
  • +5 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

Recurrent DLBCL Activated B-Cell Type, Recurrent DLBCL Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
  • +8 more
  • Biospecimen Collection
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Mar 8, 2023

Lymphoma, Lymphoma, Large B-Cell, Diffuse Trial in Boston (Glofitamab, Polatuzumab, Rituximab)

Not yet recruiting
  • Lymphoma
  • Lymphoma, Large B-Cell, Diffuse
  • Boston, Massachusetts
  • +1 more
Apr 4, 2023

Diffuse Large B-cell Lymphoma (DLBCL) Trial in Westbury (Odronextamab, Rituximab, Cyclophosphamide)

Recruiting
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Westbury, New York
    Clinical Research Alliance Inc
Oct 13, 2023

Diffuse Large B-cell Lymphoma Trial in Tampa, Philadelphia (Tisagenlecleucel, Ibrutinib)

Terminated
  • Diffuse Large B-cell Lymphoma
  • Tampa, Florida
  • +1 more
Jan 27, 2023

Large B-cell Lymphoma Trial in Houston (Prednisone, Rituximab, Cyclophosphamide)

Not yet recruiting
  • Large B-cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Sep 19, 2023

DLBCL - Diffuse Large B Cell Lymphoma, Lymphoma Trial in Shanghai (Other)

Not yet recruiting
  • DLBCL - Diffuse Large B Cell Lymphoma
  • Lymphoma
  • Other
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Sep 6, 2023

Including miRNA-based Tumor Signatures in Diffuse Large B Cell

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • no intervention (observational study)
  • Napoli, Italy
  • +2 more
Feb 17, 2023

Diffuse Large B Cell Lymphoma Trial (anti-CD19 CAR NK cells)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • anti-CD19 CAR NK cells
  • (no location specified)
Dec 21, 2022

DLBCL, DLBCL Germinal Center B-Cell Type, DLBCL, Not Otherwise Specified Trial in Columbus (Molecular Nanotechnology)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • +3 more
  • Molecular Nanotechnology
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Jun 2, 2022

Diffuse Large B Cell Lymphoma Trial in Philadelphia (Nivolumab, IV, 240 mg)

Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • Nivolumab, IV, 240 mg
  • Philadelphia, Pennsylvania
    Fox Chase Cancer Center
Jan 3, 2023

Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL

Recruiting
  • Diffuse Large B Cell Lymphoma
    • Salvador, Bahia, Brazil
    • +9 more
    Jul 24, 2023

    Diffuse Large B-cell Lymphoma Trial in Wuhan (Mitoxantrone Hydrochloride Liposome, Rituximab, Lenalidomide)

    Not yet recruiting
    • Diffuse Large B-cell Lymphoma
    • Mitoxantrone Hydrochloride Liposome
    • +2 more
    • Wuhan, Hubei, China
      Department of Hematology Tongji Hospital, Tongji Medical College
    Oct 7, 2022

    Cardiovascular Events Among Adults Relapsed or Refractory

    Recruiting
    • Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
    • +9 more
    • Electronic Health Record Review
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 5, 2022